IFNA17 and hepatitis C virus infection: Abnormal levels of serum activin-A and follistatin have been documented in several liver pathologies including viral hepatitis C. Additionally, CHC and Peg-INF-α based therapy have been recently shown to modulate the serum concentrations of both proteins.